Flemington-based Arno Therapeutics, a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, announced Thursday it has appointed Lawrence A. Kenyon as chief financial officer.
According to the announcement, Kenyon will report to president and chief executive officer Glenn Mattes, and will direct financial reporting and controls.
Kenyon has spent over a decade leading the financial function at publicly-traded healthcare companies including several in the oncology space. He has over 25-years of senior-level finance and accounting experience, the announcement said.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy